RKTO, US44148G2049

Rocket One stock faces reverse-split vote and dilution proposal

Published on 10/31/2026 at 01:49 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Rocket One stock faces a December vote on reverse-split authority and a larger equity plan. The proxy also seeks to double authorized shares.

What Rocket One shareholders will decide

Shareholders will vote on December 17, 2026, on authority for a possible reverse split ranging from 1-for-2 to 1-for-15.
The proxy seeks to raise the equity-plan reserve to 6,341,317 shares and authorized common shares to 100 million.
Neither proposed capital action would take effect before the required shareholder approval.

RKTO, US44148G2049, Illustration mit AI erstellt.

Rocket One filed its definitive proxy statement on Friday, October 23, 2026, ahead of a virtual shareholder meeting on December 17. The filing puts a potential reverse split, additional equity-plan capacity and a higher authorized-share ceiling before investors. StockTitan published the filing and its key terms.

Reverse split remains discretionary

The board is asking shareholders for authority to consolidate outstanding shares at a ratio between 1-for-2 and 1-for-15. The board would select the exact ratio and could act after approval and before December 17, 2028, without another shareholder vote. The proposal does not itself implement a reverse split.

Share capacity would expand

A separate proposal would increase the authorized common-share ceiling from 50 million to 100 million. The proxy also seeks to raise the 2022 equity-plan reserve from 3,091,317 shares to 6,341,317 shares, an increase of 3.25 million shares. Rocket One estimates that the additional plan shares could represent about 9.2 percent potential dilution, subject to shareholder approval.

The proxy states that 24,897,581 common shares were issued and outstanding as of October 22, 2026. The board recommends that shareholders vote for all six listed proposals, including the reverse-split authority, the authorized-share increase and the plan amendment.

Business remains development-led

The company website describes a therapeutics business focused on innovative treatments and patient quality of life. It highlights a pipeline aimed at unmet medical needs rather than a broad commercial product portfolio. The site presents research and development as the central activity.